171 related articles for article (PubMed ID: 12543654)
1. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.
Nannini EC; Pai SR; Singh KV; Murray BE
Antimicrob Agents Chemother; 2003 Feb; 47(2):529-32. PubMed ID: 12543654
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of eravacycline and mechanisms of resistance in enterococci.
Boukthir S; Dejoies L; Zouari A; Collet A; Potrel S; Auger G; Cattoir V
Int J Antimicrob Agents; 2020 Dec; 56(6):106215. PubMed ID: 33122095
[TBL] [Abstract][Full Text] [Related]
3. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis.
Lefort A; Lafaurie M; Massias L; Petegnief Y; Saleh-Mghir A; Muller-Serieys C; Le Guludec D; Fantin B
Antimicrob Agents Chemother; 2003 Jan; 47(1):216-22. PubMed ID: 12499194
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.
Murphy TM; Deitz JM; Petersen PJ; Mikels SM; Weiss WJ
Antimicrob Agents Chemother; 2000 Nov; 44(11):3022-7. PubMed ID: 11036017
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination.
Mercier RC; Kennedy C; Meadows C
Pharmacotherapy; 2002 Dec; 22(12):1517-23. PubMed ID: 12495161
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Gales AC; Jones RN
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M).
Fiedler S; Bender JK; Klare I; Halbedel S; Grohmann E; Szewzyk U; Werner G
J Antimicrob Chemother; 2016 Apr; 71(4):871-81. PubMed ID: 26682961
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.
Cercenado E; Cercenado S; Gómez JA; Bouza E
J Antimicrob Chemother; 2003 Jul; 52(1):138-9. PubMed ID: 12805264
[No Abstract] [Full Text] [Related]
12. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
Sum PE; Petersen P
Bioorg Med Chem Lett; 1999 May; 9(10):1459-62. PubMed ID: 10360756
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.
Wallace RJ; Brown-Elliott BA; Crist CJ; Mann L; Wilson RW
Antimicrob Agents Chemother; 2002 Oct; 46(10):3164-7. PubMed ID: 12234839
[TBL] [Abstract][Full Text] [Related]
15. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Boucher HW; Wennersten CB; Eliopoulos GM
Antimicrob Agents Chemother; 2000 Aug; 44(8):2225-9. PubMed ID: 10898710
[TBL] [Abstract][Full Text] [Related]
17. Immunological responses against vancomycin-resistant Enterococcus faecium and Enterococcus faecalis by mice.
Cho YS; Lee MH; Kim JM; Lee HS; Yoo HS; Park YH; Ryu PD
J Immunoassay Immunochem; 2018; 39(2):163-172. PubMed ID: 29308974
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China.
Sun H; Wang H; Xu Y; Jones RN; Costello AJ; Liu Y; Li G; Chen M; Mendes RE
Diagn Microbiol Infect Dis; 2012 Dec; 74(4):399-403. PubMed ID: 23099304
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Tedizolid against Enterococci and Staphylococci, Including
Singh KV; Arias CA; Murray BE
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670435
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
Tuckman M; Petersen PJ; Howe AY; Orlowski M; Mullen S; Chan K; Bradford PA; Jones CH
Antimicrob Agents Chemother; 2007 Sep; 51(9):3205-11. PubMed ID: 17620376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
